1. Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
- Author
-
Santagata, Sara, Rea, Giuseppina, Bello, Anna Maria, Capiluongo, Anna, Napolitano, Maria, Desicato, Sonia, Fragale, Alessandra, D'Alterio, Crescenzo, Trotta, Anna Maria, Ieranò, Caterina, Portella, Luigi, Persico, Francesco, Di Napoli, Marilena, Di Maro, Salvatore, Feroce, Florinda, Azzaro, Rosa, Gabriele, Lucia, Longo, Nicola, Pignata, Sandro, and Perdonà, Sisto
- Abstract
Background: Tregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in peripheral blood (PB)-Tregs isolated from primary RCC patients. Methods: PB-Tregs were isolated from 77 RCC patients and 38 healthy donors (HDs). CFSE-T effector-Tregs suppression assay, IL-35, IFN-γ, IL-10, TGF-β1 secretion, and
Nrp-1+ Tregs frequency were evaluated. Tregs were characterised for CTLA-4, PD-1, CD40L, PTEN, CD25, TGF-β1, FOXP3, DNMT1 transcriptional profile. PTEN-pAKT signalling was evaluated in the presence of R54 and/or triciribine (TCB), an AKT inhibitor. Methylation of TSDR (Treg-Specific-Demethylated-Region) was conducted. Results: R54 impaired PB-RCC-Tregs function, reducedNrp-1+ Tregs frequency, the release of IL-35, IL-10, and TGF-β1, while increased IFN-γ Teff-secretion. The CXCR4 ligand, CXCL12, recruitedCD25+PTEN+ Tregs in RCC while R54 significantly reduced it. IL-2/PMA activates Tregs reducingpAKT+ Tregs while R54 increases it. The AKT inhibitor, TCB, prevented the increase inpAKT+ Tregs R54-mediated. Moreover, R54 significantly reduced FOXP3-TSDR demethylation with DNMT1 and FOXP3 downregulation. Conclusion: R54 impairs Tregs function in primary RCC patients targeting PTEN/PI3K/AKT pathway, reducing TSDR demethylation and FOXP3 and DNMT1 expression. Thus, CXCR4 targeting is a strategy to inhibit Tregs activity in the RCC tumour microenvironment. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF